Oxidative stress related markers in the "VITA" and the centenarian projects

Neurobiology of Aging

Volumn 26, Issue 4, 2005, Pages 429-438

  Grunblatt E ^a,b   Schlosser R ^a   Fischer, P ^b,f   Fischer, M O ^a   Li, J ^a   Koutsilieri, E ^a   Wichart, I ^c   Sterba, N ^d   Rujescu, D ^g   Moller H J ^g   Adamcyk, W ^d   Dittrich, B ^d   Muller F ^d   Oberegger, K ^d   Gatterer, G ^d   Jellinger, K J ^c   Mostafaie, N ^b   Jungwirth, S ^b   Huber, K ^e   Tragl, K H ^b,e   Danielczyk, W ^b   Riederer, P ^a,b   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

^d Geriatric Center Wienerwald   (Austria)

^e DANUBE HOSPITAL   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Dementia; Diagnosis tools; Erythrocyte; Lactoferrin; MAO B; Oxidative stress; Plasma; Platelet; Superoxide dismutase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BIOCHEMICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; LACTOFERRIN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA POLYMORPHISM; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; GEOGRAPHY; HUMAN; INTRON; MALE; MORBIDITY; OXIDATIVE STRESS; PATIENT CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; AUSTRIA; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOTTING, WESTERN; COHORT STUDIES; ERYTHROCYTES; FEMALE; HUMANS; LACTOFERRIN; MALE; MENTAL STATUS SCHEDULE; MONOAMINE OXIDASE; OXIDATIVE STRESS; PLASMA; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEX FACTORS; SUPEROXIDE DISMUTASE;

EID: 19944429347     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2004.06.001     Document Type: Article

References (73)

1. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16.
2. Adolfsson R., Gottfries C.G., Oreland L., Wiberg A., Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27:1980;1029-1034
3. Alexopoulos G.S., Young R.C., Lieberman K.W., Shamoian C.A. Platelet MAO activity in geriatric patients with depression and dementia. Am J Psychiat. 144:1987;1480-1483
4. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde, Allgemeine Zeitschrift für Psychiatrie und psychiatrisch-gerichtliche. Medizin. 64:1907;146-148
5. Baker E.N., Anderson B.F., Baker H.M., MacGillivray R.T., Moore S.A., Peterson N.A., et al. Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Adv Exp Med Biol. 443:1998;1-14
6. Balciuniene J., Emilsson L., Oreland L., Pettersson U., Jazin E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet. 110:2002;1-7
7. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging. 16:1995;661-674
8. Berg L. Clinical dementia rating (CDR). Psychopharmacol Bull. 24:1988;637-639
9. Blass J. Pathophysiology of the Alzheimer's syndrome. Neurology. 43:1993;S25-S38
10. Bongioanni P., Gemignani F., Boccardi B., Borgna M., Rossi B. Platelet monoamine oxidase molecular activity in demented patients. Ital J Neurol Sci. 18:1997;151-156
11. Bonuccelli U., Piccini P., Marazziti D., Cassano G.B., Muratorio A. Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 2:1990;139-147
12. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Berl. 82:1991;239-259
13. Bradford M.M. Rapid and sensitive method for quantitation of microgram quantities of proteins utilizing principle of protein dye binding. Anal Biochem. 72:1976;248-254
14. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Publ. Health. 88:1998;1337-1342
15. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 71:2000;621S-629S
16. Cooper A. Glutathione in the brain: disorders of glutathione metabolism. In: Rosenberg R, Prusiner S, DiMauro S, Barchi R, Klunk L, editors. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann; 1997, p. 1242-45.
17. Costa P., Checkoway H., Levy D., Smith-Weller T., Franklin G.M., Swanson P.D., et al. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Genet. 74:1997;154-156
18. Damberg M., Garpenstrand H., Hallman J., Oreland L. Genetic mechanisms of behavior - don't forget about the transcription factors. Mol Psychiat. 6:2001;503-510
19. Danielczyk W., Streifler M., Konradi C., Riederer P., Moll G. Platelet MAO-B activity and the psychopathology of Parkinson's disease. Acta Psychiatr Scand. 78:1988;730-736
20. de Lustig E.S., Serra J.A., Kohan S., Canziani G.A., Famulari A.L., Dominguez R.O. Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J Neurol Sci. 115:1993;18-25
21. Double K.L., Maywald M., Schmittel M., Riederer P., Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem. 70:1998;2492-2499
22. Ekblom J., Garpenstrand H., Damberg M., Chen K., Shih J.C., Oreland L. Transcription factor binding to the core promoter of the human monoamine oxidase B gene in the cerebral cortex and in blood cells. Neurosci Lett. 258:1998;101-104
23. Fischer P., Gotz M.E., Ellinger B., Streifler M., Riederer P., Danielczyk W. Platelet monoamine oxidase B activity and vitamin B12 in dementia. Biol Psychiat. 35:1994;772-774
24. Fischer P, Jungwirth S, Krampla W, Weissgram S, Kirchmeyr W, Schreiber W, et al. Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation. J Neural Transm Suppl 2002; 105-16.
25. Fowler C.J., Wiberg A., Oreland L., Marcusson J., Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm. 49:1980;1-20
26. Fridovich I. Superoxide dismutases. Annu Rev Biochem. 44:1975;147-159
27. Garpenstrand H., Ekblom J., Forslund K., Rylander G., Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm. 107:2000;523-530
28. Gasparini L., Racchi M., Binetti G., Trabucchi M., Solerte S.B., Alkon D., et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. Faseb J. 12:1998;17-34
29. Gottfries C.G., Adolfsson R., Aquilonius S.M., Carlsson A., Eckernas S.A., Nordberg A., et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging. 4:1983;261-271
30. Götz M.E., Fischer P., Gsell W., Riederer P., Streifler M., Simanyi M., et al. Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement Geriatr Cogn Disord. 9:1998;74-77
31. Greenawalt J.W., Schnaitman C. An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J Cell Biol. 46:1970;173-179
32. Gsell W., Conrad R., Hickethier M., Sofic E., Frohlich L., Wichart I., et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem. 64:1995;1216-1223
33. Halliwell B, Gutteridge J. Free Radicals in Biology and Medicine, 3rd ed. Oxford University Press; 1999.
34. Hazel J.R., Williams E.E. The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment. Prog Lipid Res. 29:1990;167-227
35. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Brit J Psychiat. 140:1982;566-572
36. Ihara Y., Hayabara T., Sasaki K., Kawada R., Nakashima Y., Kuroda S. Relationship between oxidative stress and apoE phenotype in Alzheimer's disease. Acta Neurol Scand. 102:2000;346-349
37. Jossan S.S., Gillberg P.G., Gottfries C.G., Karlsson I., Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience. 45:1991;1-12
38. Kawamata T., Tooyama I., Yamada T., Walker D.G., McGeer P.L. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol. 142:1993;1574-1585
39. Kurth J.H., Kurth M.C., Poduslo S.E., Schwankhaus J.D. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol. 33:1993;368-372
40. Leveugle B., Faucheux B.A., Bouras C., Nillesse N., Spik G., Hirsch E.C., et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol Berl. 91:1996;566-572
41. Leveugle B., Spik G., Perl D.P., Bouras C., Fillit H.M., Hof P.R. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 650:1994;20-31
42. Licastro F., Pedrini S., Davis L.J., Caputo L., Tagliabue J., Savorani G., et al. Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis Assoc Disord. 15:2001;51-55
43. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol. 150:1998;40-44
44. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 23:1997;134-147
45. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944
46. Mellick G.D., Buchanan D.D., McCann S.J., James K.M., Johnson A.G., Davis D.R., et al. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord. 14:1999;219-224
47. Meszaros Z., Borcsiczky D., Mate M., Tarcali J., Szombathy T., Tekes K., et al. Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease. Neurochem Res. 23:1998;863-868
48. Nakamura S., Kawamata T., Akiguchi I., Kameyama M., Nakamura N., Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol (Berl). 80:1990;419-425
49. O'Connor D.W., Pollitt P.A., Hyde J.B., Brook C.P., Reiss B.B., Roth M. Do general practitioners miss dementia in elderly patients? Bmj. 297:1988;1107-1110
50. Oreland L. Monoamine oxidase in neuro-psychiatric disorders. In: Yasuhara H, Parves S, Oguchi K, Sandler M, Nagatsu T, editors. Monoamine Oxidase: Basic and Clinical Aspects. Utrecht: VSP; 1993, p. 219-47.
51. Oreland L., Gottfries C.G. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiat. 10:1986;533-540
52. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol. 140:1992;621-628
53. Parnetti L., Reboldi G.P., Santucci C., Santucci A., Gaiti A., Brunetti M., et al. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging Milano. 6:1994;201-207
54. Percy M.E., Dalton A.J., Markovic V.D., McLachlan D.R., Hummel J.T., Rusk A.C., et al. Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet. 35:1990;459-467
55. Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, et al. Reactive oxygen: its sources and significance in Alzheimer disease. J Neural Transm Suppl;2002:69-75.
56. Peskin A.V., Winterbourn C.C. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta. 293:2000;157-166
57. Riederer P, Youdim M. The therapeutic place and value of present and future MAO-B inhibitors-L-Deprenyl as the gold standard. In: Szelenyi J, editor. Inhibition of monoamine oxidase B, pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhauser; 1993, p. 327-38.
58. Saunders A.M. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol. 59:2000;751-758
59. Saura J., Luque J.M., Cesura A.M., Da Prada M., Chan-Palay V., Huber G., et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 62:1994;15-30
60. Serra J.A., Famulari A.L., Kohan S., Marschoff E.R., Dominguez R.O., de Lustig E.S. Copper-zinc superoxide dismutase activity in red blood cells in probable Alzheimer's patients and their first-degree relatives. J Neurol Sci. 122:1994;179-188
61. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA. 88:1991;10540-10543
62. Smith R.C., Ho B.T., Kralik P., Vroulis G., Gordon J., Wolff J. Platelet monamine oxidase in Alzheimer's disease. J Gerontol. 37:1982;572-574
63. Snaedal J., Kristinsson J., Gunnarsdottir S., Baldvinsson M., Johannesson T. Olafsdottir, Copper ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement Geriatr Cogn Disord. 9:1998;239-242
64. Somerville M.J., Percy M.E., Bergeron C., Yoong L.K., Grima E.A., McLachlan D.R. Localization and quantitation of 68 kDa neurofilament and superoxide dismutase-1 mRNA in Alzheimer brains. Brain Res Mol Brain Res. 9:1991;1-8
65. Song W., Zhou L.J., Zheng S.X., Zhu X.Z. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin. 21:2000;557-563
66. Sparks D.L., Woeltz V.M., Markesbery W.R. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol. 48:1991;718-721
67. Sziraki I., Mohanakumar K.P., Rauhala P., Kim H.G., Yeh K.J., Chiueh C.C. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience. 85:1998;1101-1111
68. Thome J., Gsell W., Rosler M., Kornhuber J., Frohlich L., Hashimoto E., et al. Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci. 60:1997;13-19
69. Ukeda H., Shimamura T., Tsubouchi M., Harada Y., Nakai Y., Sawamura M. Spectrophotometric assay of superoxide anion formed in maillard reaction based on highly water-soluble tetrazolium salt. Anal Sci. 18:2002;1151-1154
70. von Strauss E., Viitanen M., De Ronchi D., Winblad B., Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 56:1999;587-592
71. Weyler W., Hsu Y.P., Breakefield X.O. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther. 47:1990;391-417
72. Wurtman R. A sensitive and specific assay for the estimation of monoamine oxidase. Pharmacol Biochem Behav. 12:1963;1439-1441
73. Zhou G., Miura Y., Shoji H., Yamada S., Matsuishi T. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiat. 70:2001;229-231